Specifically, in prostate cancer, delineating SBRT target volumes based on 68Ga-PSMA-PET/CT bone uptake can enhance the precision of radiotherapy for prostate cancer bone metastases (28). This evidence concerns the gene FOLH1 and prostate carcinoma.